A runner-up in our 2017 Max Perutz Science Writing Award, PhD student Lara Morley of the Leeds Institute of Cardiovascular and Metabolic Medicine describes how she’s looking for ways to treat a failing placenta, by increasing the blood supply to the baby in the womb.
With the emergency buzzer still ringing in my ears, I feel my adrenaline subside as I bring a much anticipated new life out into the world and into the arms of its anxious parents. After all, the outcome of a pregnancy has profound implications for the lives of us all; ourselves, partners, sisters and friends. But in all the excitement of welcoming a baby into the world, the vital job of the placenta is often overlooked.
Bacteria resistant to drugs are stopping us from treating infectious diseases and undermining medical advances. So what can we do about it? This WHO Antibiotic Awareness Week Dr Jonathan Pearce, Head of Infections and Immunity at the MRC, explains why understanding how resistance develops and spreads is key to tackling antibiotic resistance. And how using this knowledge, we can find creative new ways of preventing and treating infections.
Enterobacteria grown on a selective agar plate.
Antibiotic resistance is now recognised as one of the most serious threats to human health, spreading across national boundaries. It arises from a complex interplay between biomedical, animal, social, cultural and environmental factors. If we are to meet this challenge, we need to take both an international and interdisciplinary approach.
Dr Pauline Williams leads global health research and development at GSK and recently became an MRC Council member. Here she tells us about mixing science with business, and the satisfaction of making a life-saving gel from an antiseptic mouthwash.
Dr Pauline Williams, GlaxoSmithKline. Image credit: GlaxoSmithKline
Career in brief:
- Medicine degree, University of Cardiff
- Clinical Pharmacology physician, Glaxo Phase I Unit
- Head of Academic Discovery Performance Unit, GSK
- Senior Vice President and Head of Global Health R&D, GSK
It was the rigour and excitement of early drug development that tempted me away from medicine. I did a stint at a Phase I Clinical Pharmacology Unit after my medical training – and following that I was enticed by an offer to join Glaxo (now GSK) where I’ve worked ever since. My first role was a full immersion in the design, conduct and reporting of experimental medicine studies which has stood me in good stead throughout my career.